ClinicalTrials.gg
CompletedNCT01062360Updated Sep 1, 2017

Placebo and Active Controlled Study to Assess Efficacy and Tolerability of Aspirin Plus Pseudoephedrine

A Phase 3 interventional study of Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine and Acetylsalicylic Acid (Aspirin, BAYE4465) in Common Cold and Pharyngitis, sponsored by Bayer. Completed at 59 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-09-01.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 11 months after the study started (first participant enrolled Dec 2005, registered Dec 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,016
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 10 studies in Common Cold with a site in Italy — none open to participants now, none under way, none of them phase 3. Common Cold · Italy.

Started
2005
with 1 other
Phase 3
3 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
2 of 10
Bayer

Among the 10 studies in Common Cold with a site in Italy, this one is one of 2 that started in 2005, is one of 3 in phase 3, and was the 1st registered.

Common Cold

219 studies on the registry are indexed under Common Cold; 23 are open to participants now.

Browse Common Cold studies →

Open to participants now

None of the 10 studies in Common Cold with a site in Italy is open now. The open studies under Common Cold, anywhere →

Who these studies take

Of the 14 Common Cold studies recruiting now, 4 (29%) set no upper age limit and 9 (64%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Common Cold with a site in Italy as a file.
02

Study summary

The purpose of this study is compare efficacy and tolerability of a fixed combination, containing 500 mg Acetylsalicylic acid and 30 mg Pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion.

03

Conditions studied

  • Common Cold
  • Pharyngitis

Keywords

  • Sore Throat
  • Upper Respiratory Tract Infections
  • Nasal Congestion
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:- Male and female subjects between 18 and 65 years of age.- Onset of cold symptoms within 96 hours (4 days) before study participation.- Current complaint of at least moderate sore throat at baseline- Current complaint of at least moderate NC at baseline- History of other symptoms associated with URTI during the last 4 days before study participation.- Other findings of URTI, confirmed on the physical examination.- Agreement to comply with the study requirements.- Written prior to enrollment in the study Exclusion Criteria:- Pregnant or lactating females.- Uncontrolled chronic diseases.- History of (allergic reaction) to ASA, any other nonsteroidal anti-inflammatory drugs (NSAIDs), or PSE.- Any disease which significantly compromises breathing or interferes with the subjects assessment of sore throat.- History of or active peptic ulcer.- Severe impaired hepatic function.- Severe impaired renal function.- Simultaneous intake of monoamine oxidase inhibitors.- Use of menthol containing tissues within 2 hours before first intake of study drug.- Intake of any menthol containing product within 4 hours before first intake of study drug.- Use of any local or systemic short acting cough and cold preparations within 6 hours before first intake of study drug.- Use of any local or systemic long acting cough and cold preparations within 12 hours before first intake of study drug.- Intake of any analgesic within 12 hours before first intake of study drug.- Intake or requirement of any prescription medication for the treatment of the current acute respiratory tract infection.- Current or previous intake of anticoagulants, corticoids, NSAIDs, methotrexate, or lithium.- Participation in another clinical trial within the last 30 days.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,016 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine

  • Active comparator
    Arm 2

    Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)

  • Active comparator
    Arm 3

    Drug: Pseudoephedrine

  • Placebo comparator
    Arm 4

    Drug: Placebo

Interventions

  • DrugAcetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine

    Drug pages: Aspirin · Pseudoephedrine

    Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

  • Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

  • Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

  • DrugPlacebo

    Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.

06

What researchers measure

Primary outcomes

  1. The primary efficacy parameter for the nasal congestion was the AUC calculated for baseline adjusted NCS for the initial 2 hours post dosing

    Time frame: 2 hours

  2. The primary efficacy parameter for sore throat was SPID2 hours

    Time frame: 2 hours

Secondary outcomes

  1. The Pain Intensity Difference at time point: 15, 30, 60, 90, 120, 240, and 360 minutes after the first dose

    Time frame: 15, 30, 60, 90, 120, 240, and 360 minutes

  2. The Nasal Congestion Score

    Time frame: 15, 30, 60, 90, 120, 240, and 360 minutes

  3. The Nasal Congestion Relief Score

    Time frame: 15, 30, 60, 90, 120, 240, and 360 minutes

  4. Sore throat pain relief

    Time frame: 15, 30, 60, 90, 120, 240, and 360 minutes

  5. The symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches, and pain) at 120 minutes post dose

    Time frame: 120 minutes

  6. The results of an overall assessment of treatment by the subjects at 120 minutes post dose

    Time frame: 120 minutes

  7. The results of an overall assessment of treatment by the subjects at the end of Day 3 after the first dose, or at the end of treatment (6 hours after last dose of study drug)

    Time frame: Day 3

  8. Nasal Congestion, Pain Intensity Difference and pain relief at the end of Day 2 and at the end of Day 3, or at the end of treatment (6 hours after the last study drug intake)

    Time frame: Day 3

  9. The symptoms of common cold (headache, sinus pressure/pain, feverish discomfort, muscle aches, and pain) at the end of Day 2 and at the end of Day 3, or at the end of treatment (6 hours after the last study drug intake)

    Time frame: Day 2 and Day 3

  10. Total amount of drug intake

    Time frame: Day 3

07

Study locations

59 sites
  • New York, New York 11021, United States
  • New York, New York 11743, United States
  • Alassio, 17021, Italy
  • Albenga, 17031, Italy
  • Arenzano, 16011, Italy
  • Civitella Paganico, 58048, Italy
  • Follonica, 58022, Italy
  • Genova, 16010, Italy
  • Genova, 16125, Italy
  • Genova, 16128, Italy
  • Genova, 16129, Italy
  • Genova, 16131, Italy
  • Genova, 16137, Italy
  • Genova, 16143, Italy
  • Genova, 16149, Italy
  • Genova, 16161, Italy
  • Genova, 16162, Italy
  • Grosseto, 58100, Italy
  • Grossetto, 58100, Italy
  • Isola del Cantone, 16017, Italy
  • Loano, 17025, Italy
  • Masone, 16010, Italy
  • Orbetello, 58100, Italy
  • Pegli, 16100, Italy
  • Quiliano, 17047, Italy
  • Rivarolo, 16150, Italy
  • Ronco Scrivia, 16019, Italy
  • Sampierdarena, 16151, Italy
  • Scansano, 58054, Italy
  • Serra Ricco, 16010, Italy
  • Varazze, 17019, Italy
  • Ciechocin, 87-408, Poland
  • Debowa Gora, 96-116, Poland
  • Kattowitz, 40-226, Poland
  • Kattowitz, 40-520, Poland
  • Kattowitz, 40-752, Poland
  • Krakau, 31-215, Poland
  • Lodzi, 93-105, Poland
  • Piaseczno, 05-500, Poland
  • Skierniewice, 96-100, Poland
  • Szczecin, 71-140, Poland
  • Szczecin, 71-502, Poland
  • Thorn, 87-100, Poland
  • Warszawa, 01-493, Poland
  • Warszawa, 01-961, Poland
  • Warszawa, 02-091, Poland
  • Warszawa, 02-097, Poland
  • Warszawa, 02-793, Poland
  • Warszawa, 03-185, Poland
  • Zabrze, 41-800, Poland
  • Bratislava, 81107, Slovakia
  • Bratislava, 84101, Slovakia
  • Bratislava, 84104, Slovakia
  • Bratislava, 84107, Slovakia
  • Bratislava, 85101, Slovakia
  • Bratislava, 85102, Slovakia
  • Bratislava, 85105, Slovakia
  • Pezinok, 90201, Slovakia
  • Stupava, 90031, Slovakia
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2005 to primary completion in May 2007, 16 months.

Of 17 phase 3 interventional studies under Common Cold, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2009
First posted
Feb 4, 2010
StartActual
Dec 23, 2005
Primary completionActual
May 14, 2007
CompletionActual
May 14, 2007
Last update
Sep 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01062360
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Feb 4, 2010
Start date
Dec 23, 2005
Primary completion
May 14, 2007
Completion
May 14, 2007
Last update
Sep 1, 2017

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Pseudoephedrine

Start the discussion